AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00670501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D Supplement
Description: Approximately 400 to 1200 IU/day of vitamin D will be supplied as open-label oral supplement
Study NCT04726384 — intervention group
Intervention type: DEVICE
Intervention: Assessment of physical activity level
Description: Physical activity was assessed using the Sensewear Armband device. Patients received the device on Thursday mornings, prior to exercise and treatments. The device was placed on the right arm throughout the study. Patients in whom the device monitored a minimum of 95% of the time of the study day were analyzed. Prior to the study, the devices were programmed to record a minimum level of intense (>3MET) and moderate ( >6MET) exercise.
Study NCT02508051 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Article email links
Description: Email links to specific articles, published in 2 journals M-Fr with a reminder to take the same test every six month
Study NCT02508051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blog email links
Description: Emailed web links to blog posts M-Fr based on the same articles as in Email links group; each blog post will focus on a specific article with links to the corresponding article. Every six months group 3 will get a reminder to take the same test.
Study NCT04192851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tent Pole Technique
Description: * All patients were operated under local or general anaesthesia according to the case and patient tolerability.~* The oral cavity was prepared by 0.12% chlorhexidine mouthrinses solution\* for thirty seconds.~* Full thickness incision down to the bone with blade no.15.~* A periosteal elevator was used to perform mucoperiosteal flap.~* Gentle elevation of the flap~* Fixation of the screws over the alveolar ridge with about 5 mm of the screw threads will be exposed~* Bone graft was mixed with the patient blood and placed to cover the screws completely.~* PRF membrane was be placed over the grafted sites.~* Repositioning of the flap and suturing with 3/0 black silk suture material
Study NCT04498169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil Ophthalmic
Description: Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution
Study NCT00791258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine and olmesartan medoxomil tablets
Description: amlodipine and olmesartan medoxomil tablets administered orally, once daily for up to 20 weeks
Study NCT00791258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide tablets
Description: hydrochlorothiazide tablets may be administered orally, if necessary once daily, for up to 8 weeks
Study NCT03957395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Precision Novi™ system Neurostimulation procedures
Description: SCS with Device: Precision Novi™ system
Study NCT03957395 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Device: Precision Novi™ system Neurostimulation procedures
Description: SCS with Device: Precision Novi™ system
Study NCT00357214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Bicarbonate
Description: 67.5 mmol/d given as three tablets after each meal, with a full glass of water
Study NCT00357214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate
Description: 67.5 mmol/d given as three tablets after each meal, with a full glass of water
Study NCT00357214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Chloride
Description: 67.5 mmol/d given as three tablets after each meal, with a full glass of water
Study NCT00357214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo (microcrystalline cellulose)
Description: Given as three tablets after each meal, with a full glass of water
Study NCT04110548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Task
Description: Participants are instructed to complete the emotion assessment after Look or Decrease the neutral or negative pictures. The Decrease asks the participants to use cognitive reappraisal or mindfulness strategies to decrease the intensity of emotion, whereas the Look asks the participants to look naturally at the picture. First, the look or decrease is displayed on the computer for 2 s. Then, a neutral or negative picture is presented on the screen for 7s. Finally, participants will rate the intensity of their emotion for 4s. Then, they have 1s-3s to relax before the next trial. In the meantime, Skin conductance activities will be recorded using a constant voltage with 1-cm 3 AgAg/Cl electrodes attached to the medial phalanx surfaces of the middle and index fingers of the nondominant hand.
Study NCT04110548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Craving Regulation Task
Description: Participants are instructed to complete the craving assessment after Look or Decrease the neutral or gaming pictures. The Decrease asks the participants to use cognitive reappraisal or mindfulness strategies to decrease the intensity of craving, whereas the Look asks the participants to look naturally at the picture. First, the look or decrease is displayed on the computer for 2 s. Second, a neutral or gaming picture is presented on the screen for 7s. Third, participants rate the intensity of their craving for 4s. Then, they have 1s-3s to relax before the next trial. In the meantime, Skin conductance activities will be recorded using a constant voltage with 1-cm 3 AgAg/Cl electrodes attached to the medial phalanx surfaces of the middle and index fingers of the nondominant hand.
Study NCT01789762 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous plasma
Description: Transfusions of platelet concentrates re-suspended in autologous plasma
Study NCT01789762 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Additive solution
Description: Transfusions of platelets prepared in additive solution (Intersol)
Study NCT01789762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pathogen reduction process
Description: Patients transfused with platelets treated by pathogen reduction process
Study NCT02877862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mAGIC app
Description: 7-day app to encourage uptake of genetic counseling
Study NCT03146767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetanus stabilization of baseline
Description: Administering a Tetanic stimulus before baseline stabilization shortens the stabilization period of baseline of a neuromuscular block monitor. This acts on the baseline value
Study NCT04062019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU/m2 once every other day, for 3 months.
Study NCT03083847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine Phosphate
Description: Chloroquine has been widely used for treatment and prophylaxis of malaria since 1946 (Most, London et al. 1984). It was the treatment of choice for uncomplicated malaria for decades because it was safe, well tolerated, affordable and highly effective for the treatment of malaria. However, increasing spread of chloroquine- resistant Pf over the last two decades has severely limited its use (Wellems 2002). Chloroquine phosphate is U.S Food and Drug Administration (FDA) approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf.
Study NCT03083847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Description: Pyrimethamine is a folic acid antagonist that has been commonly used as antimalarial drug for both treatment and prevention of malaria, usually in combination with sulfadoxine in adults, pregnant women, and children worldwide (Organization April 2013 (rev. January2014)
Study NCT03083847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sanaria PfSPZ Challenge
Description: Sanaria Inc has manufactured two strains of Sanaria PfSPZ Challenge: NF54 and 7G8. The Sanaria PfSPZ Challenge contains fully infectious PfSPZ purified from the salivary glands of Anopheles stephensi mosquitoes raised under aseptic conditions. The infectious PfSPZ are formulated in cryoprotectant to maintain potency for an extended period. Sanaria PfSPZ Challenge (NF54) is known to be susceptible to chloroquine, pyrimethamine, atovaquone, artesunate, but not mefloquine. Sanaria PfSPZ Challenge (7G8) is known to be susceptible to mefloquine, atovaquone, artemether and artesunate but not to chloroquine or pyrimethamine.
Study NCT03801954 — intervention group
Intervention type: BEHAVIORAL
Intervention: Educational Videos
Description: 15 videos that are about 3 minutes long each and cover nutritional advice for patients with bladder cancer undergoing RC and/or chemotherapy.
Study NCT04122404 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: LF-LAM
Description: Open label multi-center stepped wedge cluster-randomized controlled trial with implementation of LF-LAM. All clusters (i.e. HIV/ART clinic attached wards) start with standard of care and are then randomized to switch to the intervention phase at predefined time points.
Study NCT04722120 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low radiation dose CT
Description: Underwent liver CT with 30% lower radiation dose
Study NCT04722120 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CT (radiation)
Description: Underwent liver CT without change of radiation.
Study NCT04722120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low contrast dose CT
Description: Underwent liver CT 20% lower dose contrast media.
Study NCT04722120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CT (contrast agent)
Description: Underwent liver CT without change of contrast media doses.
Study NCT04722120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep-learning based contrast boosting algorithms
Description: Applied deep-learning based contrast boosting algorithms on acquired CT images
Study NCT02677948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Study NCT02677948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Study NCT01368536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valturna
Description: Valturna (aliskiren 150 mg/valsartan 160 mg) tablet
Study NCT01368536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valturna
Description: Valturna (aliskiren 150 mg/valsartan 160 mg) tablet
Study NCT02757508 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamins/minerals
Study NCT01716234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole 12 mg/kg/day BID
Description: Posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) (maximum 800 mg/day)
Study NCT01716234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole 18 mg/kg/day BID
Description: Posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) (maximum 1200 mg/day)
Study NCT01716234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole 18 mg/kg/day TID
Description: Posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) (maximum 1200 mg/day)
Study NCT01716234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole 12 mg/kg/day TID
Description: Posaconazole oral suspension 12 mg/kg/day divided into 3 doses (TID) (maximum 800 mg/day)
Study NCT06190704 — intervention group
Intervention type: DEVICE
Intervention: caIMR
Description: Coronary angiography-derived IMR (caIMR) is a novel and accurate alternative that can enable the assessment of coronary microvascular function easier, and more efficiently and does not require pressure wire or adenosine.
Study NCT03420599 — intervention group
Intervention type: PROCEDURE
Intervention: splenectomy
Description: Traumatic patients who performed total splenectomy
Study NCT02779101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab 200 mg every 3 weeks
Study NCT00516360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3.15% chlorhexidine as daily antiseptic on needleless access port
Description: 3.15% chlorhexidine as daily antiseptic on needleless access port. 1 wipe used to cleanse port each time the port is accessed
Study NCT00516360 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3.15% chlorhexidine as daily antiseptic on needleless access port
Description: 3.15% chlorhexidine as daily antiseptic on needleless access port. 1 wipe used to cleanse port each time the port is accessed
Study NCT04455256 — intervention group
Intervention type: OTHER
Intervention: x box binding protein
Description: Serum value (pg / mL) of x box binding protein (XBP-1), which is one of the unfolded proteins indicating endoplasmic reticulum stress, is measured.
Study NCT01368536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5 mg and 10 mg capsule
Study NCT01368536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone
Description: Chlorthalidone 15 mg and 25 mg capsule
Study NCT01368536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Valturna Tablet
Description: Matching placebo of valturna tablet
Study NCT01368536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Valturna Tablet
Description: Matching placebo of valturna tablet
Study NCT01368536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Capsule
Description: Matching placebo of Amlodipine capsule OR Matching placebo of chlorthalidone capsule
Study NCT01368536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Capsule
Description: Matching placebo of Amlodipine capsule OR Matching placebo of chlorthalidone capsule
Study NCT03558165 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oncomine Comprehensive Assay
Description: Stage IV lung adenocarcinoma patients will have previously biopsied tumor tissue tested with the Oncomine Comprehensive Assay
Study NCT03410849 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gastroscopy
Description: in both arms intervention 'gastroscopy' will be carried out
Study NCT04188795 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delirium Preventive Care Protocol
Description: Nursing care was applied to hip fracture patients in the experimental group in accordance with the care protocol developed to prevent delirium. Delirium preventive care protocol was consist of; psychosocial care, monitoring of oxygen saturation, prevention of dehydration, nutritional support, normal elimination, pain control, sleep regulation, avoidance of bladder catheterization and early mobilization.~Confusion Assessment Method, Barthel Index and Richards-Campbell Sleep Questionnaire were repeated to patients on the first postoperative day and on the third day.
Study NCT04263064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Volume-Low Concentration without Clonidine
Description: The control for this study will be a High Volume-Low Concentration (1.5cc/kg of 0.15% ropivacaine and 5mcg/cc epinephrine) caudal block
Study NCT04263064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Volume-Low Concentration with clonidine
Description: The study intervention will be High Volume-Low Concentration with clonidine (1.5cc/kg of 0.15% ropivacaine, with 1mcg/cc of clonidine and 5mcg/cc epinephrine).
Study NCT02319668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2% w/v Chlorhexidine digluconate
Description: Participants will brush their teeth with the reference product (toothpaste) and thoroughly rinse their mouth with water and wait 5 timed minutes before using 10 ml of the 0.2% w/v Chlorhexidine digluconate mouthwash, except when using at site, where no brushing will take place prior to using the mouthrinse.
Study NCT02319668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium fluoride toothpaste (Aquafresh Mild & Minty)
Description: Participants will apply a strip of toothpaste to cover the head of the toothbrush and will brush in their usual manner for two timed minutes twice daily. They will then rinse their mouth thoroughly with water after brushing
Study NCT02319668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium fluoride toothpaste (Aquafresh Mild & Minty)
Description: Participants will apply a strip of toothpaste to cover the head of the toothbrush and will brush in their usual manner for two timed minutes twice daily. They will then rinse their mouth thoroughly with water after brushing
Study NCT00698724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xibrom, and Optive
Description: Xibrom: two drops a day, three days before surgery and 21 days after surgery. Optive: three times a day for 21 days after surgery.
Study NCT00698724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xibrom and Pred Forte
Description: Xibrom: two drops a day, three days before surgery and 21 days after surgery. Pred Forte: three times a day for 21 days after surgery.
Study NCT02116504 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sampling of blood
Description: Sampling of blood for dosage of antibodies
Study NCT00655954 — intervention group
Intervention type: PROCEDURE
Intervention: Induced sputum
Description: Used Ultrasonic nebuliser
Study NCT02558114 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Study NCT02150148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Mentored Gardening Intervention
Description: receives raised bed or earthboxes and gardening supplies and instruction on vegetable gardening
Study NCT02150148 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Experimental: Mentored Gardening Intervention
Description: receives raised bed or earthboxes and gardening supplies and instruction on vegetable gardening
Study NCT00097747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00097747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Study NCT01495858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)
Description: Participants received one tablet of Naproxen Sodium 220 mg / Diphenhydramine hydrochloride (DPH) 25 mg and one tablet of Naproxen Sodium 220 mg, single dose, orally.
Study NCT01495858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium 440 mg (BAYH6689)
Description: Participants received two tablets of Naproxen Sodium 220 mg, single dose, orally.
Study NCT01495858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPH 50 mg
Description: Participants received two tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
Study NCT01555151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: Mometasone furoate (MF) 80 µg once daily delivered via Concept1 device; MF 200 μg once daily delivered via Concept1 device; MF 320μg once daily delivered via Twisthaler® device or 800 μg once daily delivered via Twisthaler® device
Study NCT01555151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concept 1
Description: A single dose dry powder inhaler (SDDPI)
Study NCT01555151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twisthaler
Description: A single dose dry powder inhaler (SDDPI)
Study NCT02493504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: 100units/kg of heparin were administered for the case group after dissection prior to anastomosis.
Study NCT01017588 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSU lumbar back support
Description: wear PSU back supprt during doing rubber tapper
Study NCT03130179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorette Strongmint lozenge 4 mg
Description: A single dose of one Nicorette lozenge 4mg lozenge administrated orally to slowly dissolve in the mouth.
Study NCT03130179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niquitin MiniMint lozenge 4 mg
Description: A single dose of one Niquitin Minimint lozenge 4mg administrated orally to slowly dissolve in the mouth.
Study NCT02015325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planet Water Foundation's Program
Description: Planet Water Foundation's Program (PWP) provides a school-based program with an aim to improve health outcomes in children using three components: (a) access to safe water, (b) access to hand washing facilities, and (c) access to water-health and hygiene education. As part of the PWP, access to safe water is provided through the use of an AquaTower, which incorporates an Ultra Filtration (UF) system. WASH messaging is also posted around the AquaTower as derived from PWP's school-based four week Water-Health \& Hygiene education program.
Study NCT03382015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BKR-013 or Placebo
Description: Encapsulated L-glutamine
Study NCT03382015 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BKR-013 or Placebo
Description: Encapsulated L-glutamine
Study NCT01366261 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: semirigid thoracoscopy
Description: thoracoscopy with semirigid instrument
Study NCT01366261 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rigid thoracoscopy
Description: thoracoscopy with rigid instrument
Study NCT04537546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OBESINOV elasto-compressive belt
Description: It is a customised medical device, using a technique for calculating the compression ratio adapted to each patient according to his morphology